Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Feb 22, 2019 - The index endured a holiday-shortened but volatile week.
Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Feb 20, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Feb 20, 2019 - Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Feb 19, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10.9 million of Shares, Stocks: MRK, release date:Feb 19, 2019
Feb 19, 2019 - A drug that disappointed in 2018 will get an unexpected dance at the big ball.
Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.